Democratic lawmakers are pressing the Biden administration to finalize a framework floated last year that would allow the government to use its rarely invoked march-in authority as a tool to lower the cost of expensive prescription drugs developed using U.S. taxpayer funding. President-elect Donald Trump issued an 11th-hour proposal before leaving his first term that prohibited use of march-in rights to license third parties to manufacture more affordable versions of drugs developed with federal funding. President Joe Biden quickly rescinded...